Methylglyoxal bis (cyclopentylamidinohydrazone) (MGBCP): antitumor effect against human osteosarcoma cells and combined effect with methotrexate, adriamycin and 4-hydroperoxyifosfamide.
The antitumor effect of a polyamine biosynthetic pathway inhibitor methylglyoxal bis(cyclopentylamidinohydrazone) (MGBCP) on human osteosarcoma cell lines such as KHOS-240S, MG-63 and G-292 cells, and its effect in combination with anticancer drugs such as methotrexate (MTX), adriamycin (ADM) and 4-hydroperoxyfosfamide (HIFO) have been investigated. The growth of these cultured osteosarcoma cells was inhibited by MGBCP in a dose-dependent manner. Spermidine and spermine levels were dose-dependently depressed in these MGBCP-treated osteosarcoma cells. The antitumor effect of MGBCP was additively potentiated by combined treatment with MTX, ADM and HIFO, respectively.